Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial
Brief Summary: The proposed study is a masked trial, with stratified block randomization by site, designed to determine which treatment, methotrexate or mycophenolate mofetil, is more effective as first-line steroid-sparing treatment for patients with non-infectious uveitis requiring corticosteroid-sparing therapy.

One hundred non-infectious uveitis patients in need of corticosteroid-sparing therapy will be randomized to receive either oral methotrexate or oral mycophenolate mofetil at Aravind Eye Hospitals (Madurai and Coimbatore, South India). They will be followed monthly for 6 months after enrollment or until treatment failure. The investigators hypothesize that the proportion achieving corticosteroid-sparing success at 6 months for patients taking mycophenolate mofetil will be improved in comparison with patients taking methotrexate.


Options:
A: Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: Prednisone | Arm Label: Mycophenolate Mofetil; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil, Drug: Prednisone | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Methotrexate, Mycophenolate Mofetil
B: Arm Label: AIN457C 300 mg every 2 week dosage regimen; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457C 300 mg monthly dosage regimen; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457C 300 mg every 2 week dosage regimen | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457C 300 mg monthly dosage regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: AIN457 300mg s.c weekly for 3 weeks; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 300mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 150mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: Placebo s.c weekly for 3 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c weekly for 3 weeks | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c at baseline and Week 2 | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c at baseline and Week 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c weekly for 3 weeks
D: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil

Answer: D